News

Abiomed, a provider of heart support technologies, has received 510(k) clearance from the FDA for its Impella 5.0 and Impella LD circulatory support devices. This 510(k) clearance designates

BioMS Medical has reported that the independent data safety monitoring board for the company’s pivotal Phase III Maestro-01 Canadian/European trial of dirucotide in patients with secondary progressive multiple

Esperance Pharmaceuticals has reported positive results from the company’s preclinical program that support the initiation of clinical trials in cancer. EP-100 is the first candidate from the company’s

The PSA test, as well as how it is used to guide patient care (e.g., at what age men should begin regular testing, intervals at which the test

Topica Pharmaceuticals has initiated patient enrollment in a Phase II clinical trial evaluating luliconazole for the treatment of tinea pedis. The Phase II, multi-center, randomized, double-blind trial is

The EUA authority allows the FDA, based on the evaluation of available data, to authorize the use of unapproved or uncleared medical products or unapproved or uncleared uses

Accumetrics’s VerifyNow system is a platform for measuring an individual’s response to multiple antiplatelet agents. The distribution agreement marks the beginning of several new distribution channels for the

Under the terms of the agreement, NicOx will pay Nitromed E2 million at signature and a further E4 million upon NicOx fulfilling certain future business criteria. NicOx is

Cigna said that it will review available A1C lab values for people taking any oral anti-diabetic medications, and, if at the end of the year, A1C values have